<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2102221754
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Anidulafungin BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANIDULAFUNGIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        406.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Actavis Italy SpA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Actavis Italy SpA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Anidulafungin BOS contains the active substance anidulafungin and is prescribed in adults and in paediatric patients aged 1 month to less than 18 years to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis. The infection is caused by fungal cells (yeasts) called <em>Candida</em>.</p><p>Anidulafungin BOS belongs to a group of medicines called echinocandins. These medicines are used to treat serious fungal infections.</p><p>Anidulafungin BOS prevents normal development of fungal cell walls. In the presence of Anidulafungin BOS, fungal cells have incomplete or defective cell walls, making them fragile or unable to grow.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Anidulafungin BOS</strong><strong>:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to anidulafungin, other echinocandins (e.g. caspofungin acetate), or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before using Anidulafungin BOS.</p><p>Your doctor may decide to monitor you</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for liver function more closely if you develop liver problems during your treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are given anaesthetics during your treatment with Anidulafungin BOS</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for signs of an allergic reaction such as itching, wheezing, blotchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for signs of an infusion&ndash;related reaction which could include a rash, hives, itching, redness,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for shortness of breath/breathing difficulties, dizziness or light-headedness</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Anidulafungin BOS should not be given to patients under 1 month of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Anidulafungin BOS</strong></p><p>Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>The effect of Anidulafungin BOS in pregnant women is not known. Therefore, Anidulafungin&nbsp;BOS is not recommended during pregnancy. Effective contraception should be used in women of childbearing age. Contact your doctor immediately if you become pregnant while taking Anidulafungin BOS.</p><p>The effect of Anidulafungin BOS in breast-feeding women is not known. Ask your doctor or pharmacist for advice before taking Anidulafungin BOS while breast-feeding.</p><p>Ask your doctor or pharmacist for advice before taking any medicines.</p><p><strong>Anidulafungin BOS contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Anidulafungin BOS will always be prepared and given to you or your child by a doctor or a healthcare professional (there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only).</p><p>&nbsp;</p><p>For use in children and adolescents (age from 1 month to less than 18 years), the treatment starts with 3.0 mg/kg (not to exceed 200 mg) on the first day (loading dose). This will be followed by a daily dose of 1.5 mg/kg (not to exceed 100 mg) (maintenance dose). The dose that is given depends on the patient&rsquo;s weight.</p><p>&nbsp;</p><p>For use in adults, the treatment starts with 200 mg on the first day (loading dose). This will be followed by a daily dose of 100 mg (maintenance dose).</p><p>Anidulafungin BOS should be given to you once a day, by slow infusion (a drip) into your vein. For adults, this will take at least 1.5 hours for the maintenance dose and 3 hours for the loading dose. For children and adolescents, the infusion may take less time depending on the patient&rsquo;s weight.</p><p>&nbsp;</p><p>Your doctor will determine the duration of your treatment and how much Anidulafungin BOS you will receive each day and will monitor your response and condition.</p><p>In general, your treatment should continue for at least 14 days after the last day Candida was found in your blood.</p><p>&nbsp;</p><p><strong>If you receive more Anidulafungin BOS than you should</strong></p><p>If you are concerned that you may have been given too much Anidulafungin BOS, tell your doctor or another healthcare professional immediately.</p><p>&nbsp;</p><p><strong>If you forgot to use </strong><strong>Anidulafungin BOS</strong></p><p>As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.</p><p>You should not be given a double dose by doctor.</p><p>&nbsp;</p><p><strong>If you stop using </strong><strong>Anidulafungin BOS</strong></p><p>You should not experience any effects from Anidulafungin BOS if your doctor stops Anidulafungin BOS treatment.</p><p>Your doctor may prescribe another medicine following your treatment with Anidulafungin BOS to continue treating your fungal infection or prevent it from returning.</p><p>If your original symptoms come back, tell your doctor or another healthcare professional immediately.</p><p>If you have any further questions on the use of this medicine, ask your doctor, or pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some of these side effects will be noted by your doctor while monitoring your response and condition.</p><p>&nbsp;</p><p>Life-threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have been rarely reported during administration of Anidulafungin BOS.</p><p>Serious side effects &ndash; tell your doctor or another healthcare professional immediately should any of the following occur:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion (seizure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, pruritis (itching)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden contraction of the muscles around the airways resulting in wheezing or coughing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty of breathing</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p><strong>Very common side effects (may affect more than 1 in 10 people) are:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood potassium (hypokalaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people) are:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion (seizure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood tests of liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, pruritis (itching)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood tests of kidney function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal flow of bile from the gallbladder into the intestine (cholestasis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden contraction of the muscles around the airways resulting in wheezing or coughing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty of breathing</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) are:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorder of blood clotting system</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain at injection site</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data) are:</strong></p><p>- Life-threatening allergic reaction</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2℃ &ndash; 8℃).</p><p>The reconstituted solution may be stored up to 25℃ for up to 24 hours. The infusion solution may be stored at 25℃ (room temperature) for 48 hours, (do not freeze) and should be administered at 25℃ (room temperature) within 48 hours.</p><p>Do not throw away any medicines via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Anidulafungin BOS contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is anidulafungin. Each vial contains 100 mg anidulafungin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are tartaric acid, sucrose, polysorbate 80, sodium hydroxide, hydrochloric acid.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Anidulafungin BOS is white to off white powder. Anidulafungin BOS is packaged in type I colorless glass vials, closed with type I butyl rubber stopper and aluminum metallic caps with polypropylene disk.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Boton Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي Anidulafungin BOS على المادة الفعالة anidulafungin التي تُوصف للمرضى البالغين والأطفال من عمر الشهر لأقل من 18 سنة لمعالجة نوع من العدوى الفُطرية التي تُصيب الدم أو الأعضاء الداخلية والتي تُسمى داء المُبيضَّات الغازية. تحدث هذه العدوى بسبب خلايا فُطريَّة (خمائر) تُسمى المُبيضَّات.</p><p dir="RTL">ينتمي Anidulafungin BOS لمجموعة دوائية تُسمَّى echinocandins، وتُستخدم هذه الأدوية في معالجة العدوى الفُطريَّة الخطيرة.</p><p dir="RTL">يوقف Anidulafungin BOS النمو الطبيعي لجدر الخلايا الفُطرية، فيجعلها ناقصة أو مَعيبة، وهذا ما يجعلها هشة أو غير قادرة على النمو.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم </strong><strong>Anidulafungin BOS</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتحسس من Anidulafungin أو من بقية أفراد echinocandins (مثلcaspofungin acetate)، أو أي من مكونات هذا الدواء (مذكورة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك، أو الممرضة، أو الصيدلاني قبل استخدام Anidulafungin BOS.</p><p dir="RTL">قد يُقرر طبيبك مراقبتك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من حيث وظائف الكبد إذا تطورت لديك مشاكل كبدية أثناء العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستُعطى أدوية للتخدير أثناء تلقيك العلاج بـ Anidulafungin BOS.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بحثاً عن علامات حساسية مثل الحكَّة، والأزيز، وتبقُّع الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بحثاً عن علامات التفاعلات المُتعلِّقة بتسريب الدواء مثل الطَّفح، والشَّرى، والحكة، والاحمرار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من أجل ضيق النَّفس/ أو صعوبات التنفُّس، الدَّوخة أو الشعور بالدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب ألَّا يُعطى Anidulafungin BOS للمرضى الذين تقل أعمارهم عن شهر واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>Anidulafungin BOS</strong><strong> مع الأدوية الأخرى</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني إذا كنت أنت أو طفلك تتناول دواءً آخر، أو أنَّك تناولته حديثاً، أو أنك قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع </strong></p><p dir="RTL">لا يُوصى باستخدام Anidulafungin BOS خلال الحمل لأنَّ تأثيراته غير معروفة عند النساء الحوامل، ويجب أن تستخدم النساء في سن الإنجاب وسائل منع حمل فعالة.</p><p dir="RTL">يجب عليكِ إخبار طبيبك على الفور إن أصبحتِ حاملاً خلال تلقيكِ ـ Anidulafungin BOS.</p><p dir="RTL">لا تُعرف تأثيرات Anidulafungin BOS على النساء المُرضعات، استشيري طبيبك أو الصيدلاني قبل أن تُباشري باستخدام Anidulafungin BOS خلال الإرضاع.</p><p dir="RTL">استشيري طبيبك أو الصيدلاني قبل تناولكِ لأي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مُحتوى </strong><strong>Anidulafungin BOS</strong><strong> من الصوديوم</strong></p><p dir="RTL">يحتوي Anidulafungin BOS على أقل من 1ميلي مول من الصوديوم (ما يُعادل 23ملغ) للزجاجة، لذا يُمكن القول بانَّه خالٍ من الصوديوم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يقوم الطبيب أو مقدِّمي الرعاية الصحيَّة دائماً بعمليَّة تحضير الدواء وإعطائه لك أو لطفلك (يُوجد المزيد من المعلومات حول كيفية تحضير الدواء في نهاية النشرة في قسم مُعد فقط للأطباء ومُقدِّمي الرعاية الصحية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تبدأ المُعالجة للأطفال والمراهقين (من عمر شهر واحد لأقل من 18 سنة) بـ 3ملغ/كغ (على ألا تتجاوز 200 ملغ) في اليوم الأول (الجرعة المبدئية)، ثم تُتبع بجرعة يوميَّة 1.5 ملغ/ كغ (على ألا تتجاوز 100 ملغ) (جرعة الاستمرار)، وتعتمد الجُرعة المُعطاة على وزن المريض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تبدأ المُعالجة عند البالغين بـ 200 ملغ في اليوم الأول (جرعة مبدئية)، ثم تُتبع بجرعة يومية 100 ملغ (الجرعة الاستمرارية).</p><p dir="RTL">يجب أن يُعطى Anidulafungin BOS لك مرة واحدة في اليوم، وبالتخفيف البطيء (تنقيط) في وريدك.</p><p dir="RTL">يحتاج التخفيف عند البالغين إلى ساعة ونصف على الأقل لجرعة الاستمرار، وإلى ثلاث ساعات للجرعة المبدئية. ويمكن أن يحتاج الأطفال والمراهقون إلى وقتٍ أقل اعتماداً على أوزان المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يُحدِّد طبيبك مُدة علاجك والجرعة التي سوف تتلقاها من Anidulafungin BOS يومياً، كما سيقوم بمراقبة استجابتك للعلاج ويُتابع حالتك.</p><p dir="RTL">يجب أن تستمر معالجتك بشكل عام لمدة 14 يوم على الأقل بعد آخر عينة دموية لك وُجدت فيها المبيضَّات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تَلقَّيت جرعة</strong> <strong>أكثر من اللازم من </strong><strong>Anidulafungin BOS</strong></p><p dir="RTL">أخبر طبيبك أو مقدمي الرعاية الصحية إذا كنت قلقاً من أنَّك قد أُعطيت جرعة زائدة من Anidulafungin BOS.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أخذ </strong><strong>Anidulafungin BOS</strong></p><p dir="RTL">من غير المحتمل أن يتم نسيان إحدى الجرعات، لأنك سوف تُعطى الدواء تحت مُراقبة طبية <s>لصيقة</s>. وعلى كل حال قم بإخبار طبيبك أو الصيدلاني إذا كُنت تعتقد أنَّه قد تم نسيان أحد الجرعات. ويجب على الطبيب ألَّا يعطيك جرعة مُضاعفة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا أوقفت استخدام </strong><strong>Anidulafungin BOS</strong></p><p dir="RTL">يجب ألَّا تُعاني من أي تأثيرات من Anidulafungin BOS بعد أن يُوقف طبيبك علاجك بمستحضر Anidulafungin BOS.</p><p dir="RTL">يُمكن أن يصف لك طبيبك دواءً آخر بعد مُعالجتك بمستحضر ـ Anidulafungin BOSلعلاج العدوى الفُطرية أو لمنع حدوثها مره اخرى.</p><p dir="RTL">أخبر طبيبك أو أحد مقدِّمي الرعاية الصحية على الفور إن عادت أعراضك الأصليَّة.</p><p dir="RTL">اسأل طبيبك، أو الصيدلاني، أو الممرضة إن كانت لديك استفسارات أخرى حول استخدام الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كجميع الأدوية، يُمكن أن يُسبب هذا الدواء بعض التأثيرات الجانية، على الرغم من أنَها قد لا تحصل عند جميع المرضى.</p><p dir="RTL">يُمكن لطبيبك مُلاحظة بعض من هذه التأثيرات أثناء مراقبة استجابتك للدواء ومُتابعة حالتك.</p><p dir="RTL">نادراً ما سُجِّلت علامات الحساسية المُهدِّدة للحياة أثناء إعطاء Anidulafungin BOS والتي تشمل صعوبة التنفس إضافة للأزيز أو تفاقم الطفح الجلدي الموجود.</p><p dir="RTL">التأثيرات الجانبية الخطيرة -أخبر طبيبك أو أي من مقدِّمي الرعاية الصحية الآخرين مُباشرةً إذا حصل أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج (نَوبَة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توهُّج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طَفح، حكَّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبَّات ساخنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شَرَى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنُّج مُفاجئ للعضلات حول مجرى الهواء مما يُؤدِّي إلى الأزيز والسعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التَّأثيرات الجانبية الأخرى</strong></p><p dir="RTL"><strong>التأثيرات الجابية الشائعة جداً (ربما تُؤثر على أكثر من شخص من كل 10 أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص بوتاسيوم بالدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة (ربما تؤثر على شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تشنج (نوبة)</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الصداع</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الاعياء</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تغيُّر في فحوصات الدم لوظائف الكبد</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الطفح، الحكة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تغيُّر في فحوصات الدم لوظائف الكلية</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>جريان غير طبيعي للصفراء من المرارة نحو الأمعاء الدقيقة (ركود صفراوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع سكر الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنُّج مُفاجئ للعضلات حول مجرى الهواء مما يُؤدِّي إلى الأزيز والسعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة (ربما تؤثر على شخص واحد من كل 100 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب جهاز تخثُّر الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توهُّج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبَّات ساخنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شَرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موقع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (</strong><strong>لم يتم تحديد تكرارية حدوثها من خلال البيانات المتوفرة</strong><strong>) وهي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية مُهددة للحيا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد انتهاء تاريخ الصلاحية المُدوَّن على العلبة. يُشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">خزِّن الدواء في البرَّاد (بدرجة حرارة 2-8&ordm; مئوية).</p><p dir="RTL">يمكن أن يُخزَّن المحلول المُحضَّر بدرجة حرارة تصل لـ 25&ordm; مئوية لمدة تصل لـ 24 ساعة. ويُمكن أن يُخزَّن محلول التخفيف في درجة حرارة &ordm;25 مئوية (درجة حرارة الغرفة) لمدة 48 ساعة، (لا تقم بتجميده) ويجب أن يُعطى بدرجة حرارة &ordm;25 مئوية خلال 48 ساعة.</p><p dir="RTL">لا تتخلص من أي دواء في الماء المستعمل أو مخلفات المنزل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المادة الفعالة هي anidulafungin. تحتوي كل زجاجة على 100 ملغ من anidulafungin.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المكونات الأخرى هي حمض الطرطر، والسكروز، والبولي سوربات 80، وهيدروكسيد الصوديوم، وحمض كلور الماء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما هو مظهر <strong>Anidulafungin BOS</strong><strong> وما هي محتويات العلبة؟</strong></p><p dir="RTL">Anidulafungin BOS هو مسحوق يتراوح لونه من الأبيض إلى الأبيض الفاتح، موضوع في زجاجة شفافة 40 مل من النمط الأول، مُغلقة بسدادة من المطاط البوتيلي من النمط الأول وغطاء معدني من الألمنيوم مع قرص من البولي بروبيلين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;- مالك حقوق التسويق والتغليف الثانوي:</p><p dir="RTL">شركة بوستن اونكولجي العربية</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL">ب&zwnj;- التصنيع الكامل والتغليف الأولي:</p><p dir="RTL">اكتافيس ايطاليا اس بي ايه</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Anidulafungin TBM
Anidulafungin powder for concentrate for solution for infusion 100 mg/vial.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 100 mg anidulafungin.
The reconstituted solution contains 3.33 mg/mL anidulafungin and the diluted solution contains
0.77 mg/mL anidulafungin.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion. Anidulafungin TBM is white to off white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to &lt;18 years (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Anidulafungin TBM should be initiated by a physician experienced in the management of invasive fungal infections.</p><p>&nbsp;</p><p><u>Posology</u></p><p>Specimens for fungal culture should be obtained prior to therapy. Therapy may be initiated before culture results are known and can be adjusted accordingly once they are available.</p><p><em>Adult population (dosing and treatment duration)</em></p><p>A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter. Duration of treatment should be based on the patient&#39;s clinical response.</p><p>In general, antifungal therapy should continue for at least 14 days after the last positive culture. There are insufficient data to support the 100 mg dose for longer than 35 days of treatment.</p><p><em>Patients with renal and hepatic impairment</em></p><p>No dosing adjustments are required for patients with mild, moderate, or severe hepatic impairment. No dosing adjustments are required for patients with any degree of renal insufficiency, including those on dialysis. Anidulafungin TBM can be given without regard to the timing of haemodialysis (see section 5.2).</p><p><em>Other special populations</em></p><p>No dosing adjustments are required for adult patients based on gender, weight, ethnicity, HIV positivity, or elderly (see section 5.2).</p><p><em>Paediatric population (1 month to &lt; 18 years) (dosing and treatment duration)</em></p><p>A single loading dose of 3.0 mg/kg (not to exceed 200 mg) should be administered on Day 1 followed by a daily maintenance dose of 1.5 mg/kg (not to exceed 100 mg) thereafter.</p><p>Duration of treatment should be based on the patient&#39;s clinical response.</p><p>In general, antifungal therapy should continue for at least 14 days after the last positive culture.</p><p>The safety and efficacy of Anidulafungin TBM have not been established in neonates (&lt; 1 month old) (see section 4.4).</p><p>Method of administration</p><p>For intravenous use only.</p><p>Anidulafungin TBM should be reconstituted with water for injection to a concentration of</p><p>3.33 mg/mL and subsequently diluted to a concentration of 0.77 mg/mL for the final infusion solution. For a paediatric patient, the volume of infusion solution required to deliver the dose will vary depending on the weight of the child. For instructions on reconstitution of the medicinal product before administration (see section 6.6).</p><p>It is recommended that Anidulafungin TBM be administered at a rate of infusion that does not exceed 1.1 mg/min (equivalent to 1.4 mL/min when reconstituted and diluted per instructions). Infusion associated reactions are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/min (see section 4.4).</p><p>Anidulafungin TBM must not be administered as a bolus injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity to other medicinal products of the echinocandin class.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anidulafungin has not been studied in patients with <em>Candida endocarditis</em>, osteomyelitis or meningitis. The efficacy of Anidulafungin has only been evaluated in a limited number of neutropenic patients (see section 5.1).</p><p><u>Paediatric population</u></p><p>Treatment with Anidulafungin in neonates (&lt; 1 month old) is not recommended. Treating neonates requires consideration for coverage of disseminated candidiasis including central nervous system (CNS); nonclinical infection models indicate that higher doses of anidulafungin are needed to achieve adequate CNS penetration (see section 5.3), resulting in higher doses of polysorbate 80, a formulation excipient. High doses of polysorbates have been associated with potentially life-threatening toxicities in neonates as reported in the literature.</p><p><strong><u>There is no clinical data to support the efficacy and safety of higher doses of anidulafungin</u> <u>than recommended in 4.2.</u></strong></p><p><u>Hepatic effects</u></p><p>Increased levels of hepatic enzymes have been seen in healthy subjects and patients treated with anidulafungin. In some patients with serious underlying medical conditions who were receiving multiple concomitant medicines along with anidulafungin, clinically significant hepatic abnormalities have occurred. Cases of significant hepatic dysfunction, hepatitis, and hepatic failure were uncommon in clinical trials. Patients with increased hepatic enzymes during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy.</p><p><u>Anaphylactic reactions</u></p><p>Anaphylactic reactions, including shock, were reported with the use of anidulafungin. If these reactions occur, anidulafungin should be discontinued and appropriate treatment administered.</p><p><u>Infusion-related reactions</u></p><p>Infusion-related adverse events have been reported with anidulafungin, including rash, urticaria, flushing, pruritus, dyspnoea, bronchospasm and hypotension. Infusion-related adverse events are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/min (see section 4.8).</p><p>Exacerbation of infusion-related reactions by co-administration of anaesthetics has been seen in a non-clinical (rat) study (see section 5.3). The clinical relevance of this is unknown. Nevertheless, care should be taken when co-administering anidulafungin and anaesthetic agents.</p><p><u>Sodium content</u></p><p>AnidulafunginTBM contains less than 1 mmol sodium (23 mg) per vial. Patients on low sodium diets can be informed that this medicinal product is essentially &#39;sodium-free&#39;.</p><p>&nbsp;</p><p>Anidulafungin TBM may be diluted with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A). Of note, <em>in vitro </em>studies do not fully exclude possible <em>in vivo </em>interactions.</p><p>Drug interaction studies were performed with anidulafungin and other medicinal products likely to be co-administered. No dosage adjustment of either medicinal product is recommended when anidulafungin is co-administered with ciclosporin, voriconazole or tacrolimus, and no dosage adjustment for anidulafungin is recommended when co-administered with amphotericin B or rifampicin.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of anidulafungin in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Anidulafungin is not recommended during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p><u>Breast-feeding</u></p><p>It&nbsp;&nbsp;&nbsp;&nbsp; is&nbsp;&nbsp;&nbsp;&nbsp; unknown&nbsp;&nbsp;&nbsp;&nbsp; whether&nbsp;&nbsp;&nbsp;&nbsp; anidulafungin&nbsp;&nbsp;&nbsp;&nbsp; is&nbsp;&nbsp;&nbsp;&nbsp; excreted&nbsp;&nbsp;&nbsp;&nbsp; in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; human&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; milk.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Available pharmacodynamic/toxicological data in animals have shown excretion of anidulafungin in milk.</p><p>&nbsp;</p><p>A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Anidulafungin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>For anidulafungin, there were no effects on fertility in studies conducted in male and female rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Infusion-related adverse reactions have been reported with anidulafungin in clinical studies, including rash, pruritus dyspnoea, bronchospasm, hypotension (common events), flushing, hot flush and urticaria (uncommon events), summarized in Table 1(see section 4.4).</p><p><u>Tabulated list of adverse reactions</u></p><p>The following table includes, the all-causality adverse reactions (MedDRA terms) from 840 subjects receiving 100 mg anidulafungin with frequency corresponding to very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to</p><p>&lt;1/1,000), very rare (&lt;1/10,000) and from spontaneous reports with frequency not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>Table 1. Table of Adverse Reactions</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very </strong><strong>Common</strong></p><p><strong>&ge; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1000 to &lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000</strong></p><p><strong>to</strong></p><p><strong>&lt;1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>&lt;</strong><strong> 1/10,000</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Coagulopathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock, anaphylactic reaction*</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion, headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension, hypertension</p></td><td style="vertical-align:top"><p>Flushing, hot flush</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm, Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Abdominal pain upper</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased,</p><p>blood alkaline phosphatase increased, aspartate aminotransferase increased,</p><p>blood bilirubin increased, cholestasis</p></td><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very </strong><strong>Common</strong></p><p><strong>&ge; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1000 to &lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000</strong></p><p><strong>to</strong></p><p><strong>&lt;1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>&lt;</strong><strong> 1/10,000</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infusion site pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* See section 4.4.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety of anidulafungin was investigated in 68 paediatric patients (1 month to &lt; 18 years) with ICC in a prospective, open-label, non-comparative paediatric study (see section 5.1). The frequencies of certain hepatobiliary adverse events, including alanine aminotransferase (ALT) increased and aspartate aminotransferase (AST) increased appeared at a higher frequency (7-10%) in these paediatric patients than has been observed in adults (2%). Although chance or differences in underlying disease severity may have contributed, it cannot be excluded that hepatobiliary adverse reactions occur more frequently in paediatric patients compared to adults.</p><p>To report any side effect(s):</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>&bull;&nbsp; <strong><u>Saudi Arabia</u></strong></p><p>The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&bull;&nbsp; <strong><u>Other GCC States:</u></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with any overdose, general supportive measures should be utilised as necessary. In case of overdose, adverse reactions may occur as mentioned in section 4.8.</p><p>During clinical trials, a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse reactions were reported. No dose limiting toxicity was observed in a study of 10 healthy subjects administered a loading dose of 260 mg followed by 130 mg daily; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations (&le;3 x Upper Limit of Normal (ULN)).</p><p>During a paediatric clinical trial, one subject received two doses of anidulafungin that were 143% of the expected dose. No clinical adverse reactions were reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, other antimycotics for systemic use, ATC code: JO2AX06</p><p><u>Mechanism of action</u></p><p>Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of <em>Aspergillus nidulans</em>.</p><p>Anidulafungin selectively inhibits 1,3-&beta;-D glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-&beta;-D-glucan, an essential component&nbsp; of&nbsp; the&nbsp; fungal&nbsp; cell&nbsp; wall.&nbsp; Anidulafungin&nbsp; has&nbsp; shown&nbsp; fungicidal&nbsp; activity</p><p>&nbsp;</p><p>against <em>Candida </em>species and activity against regions of active cell growth of the hyphae of <em>Aspergillus fumigatus</em>.</p><p><u>Activity <em>in vitro</em></u></p><p>Anidulafungin&nbsp; exhibited <em>in-vitro </em>activity&nbsp; against <em>C.&nbsp; albicans,&nbsp; C.&nbsp; glabrata,&nbsp; C.&nbsp; parapsilosis,</em></p><p><em>C. krusei </em>and <em>C. tropicalis. </em>For the clinical relevance of these findings see &ldquo;Clinical efficacy and safety.&rdquo;</p><p>Isolates with mutations in the hot spot regions of the target gene have been associated with clinical failures or breakthrough infections. Most clinical cases involve caspofungin treatment. However, in animal experiments these mutations confer cross resistance to all three echinocandins and therefore such isolates are classified as echinocandin resistant until further clinical experience are obtained concerning anidulafungin.</p><p>The <em>in vitro </em>activity of anidulafungin against <em>Candida </em>species is not uniform. Specifically, for <em>C. parapsilosis, </em>the MICs of anidulafungin are higher than are those of other <em>Candida </em>species.</p><p>A standardized technique for testing the susceptibility of Candida species to anidulafungin as well as the respective interpretative breakpoints has been established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><u>Table 2. EUCAST Breakpoints</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Candida Species</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><u>MIC breakpoint (mg/L)</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&le;S (Susceptible)</strong></p></td><td style="vertical-align:top"><p><strong>&gt;R (Resistant)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans</em></p></td><td style="vertical-align:top"><p>0.03</p></td><td style="vertical-align:top"><p>0.03</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata</em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis</em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei</em></p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis<sup>1</sup></em></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p><em>Other Candida spp</em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1</sup></strong><strong> </strong>Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific <em>Candida </em>species. They are for use only for organisms that do not have specific breakpoints.</p></td></tr></tbody></table><p><u>Activity <em>in vivo</em></u></p><p>Parenterally administered anidulafungin was effective against <em>Candida </em>species in immunocompetent and immunocompromised mouse and rabbit models. Anidulafungin treatment prolonged survival and also reduced the organ burden of <em>Candida </em>species, when determined at intervals from 24 to 96 hours after the last treatment.</p><p>Experimental infections included disseminated <em>C. albicans </em>infection in neutropenic rabbits, oesophageal/oropharyngeal infection of neutropenic rabbits with fluconazole-resistant <em>C. albicans </em>and disseminated infection of neutropenic mice with fluconazole-resistant <em>C. glabrata.</em></p><p><u>Clinical efficacy and safety</u></p><p><em>Candidaemia and other forms of Invasive Candidiasis</em></p><p>The safety and efficacy of anidulafungin were evaluated in a pivotal Phase 3, randomised, double-blind, multicentre, multinational study of primarily non-neutropenic patients with candidaemia and a limited number of patients with deep tissue Candida infections or with abscess-forming disease. Patients with <em>Candida </em>endocarditis, osteomyelitis or meningitis, or those with infection due to <em>C. krusei</em>, were specifically excluded from the study. Patients were randomised to receive either anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) or fluconazole (800 mg intravenous loading dose followed by 400 mg intravenous daily), and were stratified by APACHE II score (&le;20 and &gt;20) and the presence or absence of neutropaenia. Treatment was administered for at least 14 and not more than 42 days. Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medicinal products and were afebrile for at least 24 hours, and that the most recent blood cultures were negative for <em>Candida </em>species.</p><p>Patients who received at least one dose of study medicinal products and who had a positive culture for <em>Candida </em>species from a normally sterile site before study entry were included in the modified intent-to-treat (MITT) population. In the primary efficacy analysis, global response in the MITT populations at the end of intravenous therapy, anidulafungin was compared to fluconazole in a</p><p>&nbsp;</p><p>pre-specified two-step statistical comparison (non-inferiority followed by superiority). A successful global response required clinical improvement and microbiological eradication. Patients were followed for six weeks beyond the end of all therapy.</p><p>Two hundred and fifty-six patients, ranging from 16 to 91 years in age, were randomised to treatment and received at least one dose of study medication. The most frequent species isolated at baseline were <em>C. albicans </em>(63.8% anidulafungin, 59.3% fluconazole), followed by <em>C. glabrata </em>(15.7%, 25.4%), <em>C. parapsilosis </em>(10.2%, 13.6%) and <em>C. tropicalis </em>(11.8%, 9.3%) - with 20, 13 and 15 isolates of the last 3 species, respectively, in the anidulafungin group. The majority of patients had Apache II scores &le; 20 and very few were neutropenic.</p><p>Efficacy data, both overall and by various subgroups, are presented below in Table 3.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 3. </strong>Global success in the MITT population: primary and secondary endpoints</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Anidulafungin</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Fluconazole</p></td><td style="vertical-align:top"><p>Between group difference <sup>a</sup></p><p>( 95% CI)</p></td></tr><tr><td style="vertical-align:top"><p><strong>End of IV Therapy (1&deg;endpoint)</strong></p></td><td style="vertical-align:top"><p><strong>96/127 (75.6%)</strong></p></td><td style="vertical-align:top"><p><strong>71/118 (60.2%)</strong></p></td><td style="vertical-align:top"><p><strong>15.42 (3.9, 27.0)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Candidaemia only</p></td><td style="vertical-align:top"><p>88/116 (75.9%)</p></td><td style="vertical-align:top"><p>63/103 (61.2%)</p></td><td style="vertical-align:top"><p>14.7 (2.5, 26.9)</p></td></tr><tr><td style="vertical-align:top"><p>Other sterile sites<sup>b</sup></p></td><td style="vertical-align:top"><p>8/11 (72.7%)</p></td><td style="vertical-align:top"><p>8/15 (53.3%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal fluid/IA<sup>c</sup> abscess</p></td><td style="vertical-align:top"><p>6/8</p></td><td style="vertical-align:top"><p>5/8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Other</p></td><td style="vertical-align:top"><p>2/3</p></td><td style="vertical-align:top"><p>3/7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>C. albicans</em><sup>d</sup></p></td><td style="vertical-align:top"><p>60/74 (81.1%)</p></td><td style="vertical-align:top"><p>38/61 (62.3%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Non-<em>albicans </em>species<sup>d</sup></p></td><td style="vertical-align:top"><p>32/45 (71.1%)</p></td><td style="vertical-align:top"><p>27/45 (60.0%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Apache II score &le; 20</p></td><td style="vertical-align:top"><p>82/101 (81.2%)</p></td><td style="vertical-align:top"><p>60/98 (61.2%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Apache II score &gt; 20</p></td><td style="vertical-align:top"><p>14/26 (53.8%)</p></td><td style="vertical-align:top"><p>11/20 (55.0%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Non-neutropenic <strong>(ANC, cells/mm<sup>3</sup>&gt; 500)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>94/124 (75.8%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>69/114 (60.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic <strong>(ANC, cells/mm<sup>3</sup> &le;500)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2/3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2/4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p><strong>At Other Endpoints</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>End of All Therapy</p></td><td style="vertical-align:top"><p>94/127 (74.0%)</p></td><td style="vertical-align:top"><p>67/118 (56.8%)</p></td><td style="vertical-align:top"><p>17.24 (2.9, 31.6)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>2 Week Follow-up</p></td><td style="vertical-align:top"><p>82/127 (64.6%)</p></td><td style="vertical-align:top"><p>58/118 (49.2%)</p></td><td style="vertical-align:top"><p>15.41 (0.4, 30.4)<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>6 Week Follow-up</p></td><td style="vertical-align:top"><p>71/127 (55.9%)</p></td><td style="vertical-align:top"><p>52/118 (44.1%)</p></td><td style="vertical-align:top"><p>11.84 (-3.4, 27.0)<sup>e</sup></p></td></tr></tbody></table><p><sup>a</sup> Calculated as anidulafungin minus fluconazole</p><p><sup>b</sup>With or without concurrent candidaemia</p><p><sup>c</sup> Intra-abdominal</p><p><sup>d</sup> Data presented for patients with a single baseline pathogen.</p><p><sup>e</sup> 98.3% confidence intervals, adjusted post hoc for multiple comparisons of secondary time points.</p><p>&nbsp;</p><p>Mortality rates in both the anidulafungin and fluconazole arms are presented below in Table 4:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 4. </strong>Mortality</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anidulafungin</p></td><td style="vertical-align:top"><p>Fluconazole</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall study mortality</strong></p></td><td style="vertical-align:top"><p><strong>29/127 (22.8%)</strong></p></td><td style="vertical-align:top"><p><strong>37/118 (31.4%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mortality during study therapy</p></td><td style="vertical-align:top"><p>10/127 (7.9%)</p></td><td style="vertical-align:top"><p>17/118 (14.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Mortality attributed to <em>Candida </em>infection</p></td><td style="vertical-align:top"><p>2/127 (1.6%)</p></td><td style="vertical-align:top"><p>5/118 (4.2%)</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional Data in Neutropenic Patients</p><p>The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult neutropenic patients (defined as absolute neutrophil count &le; 500 cells/mm<sup>3</sup>, WBC &le;500 cells/mm<sup>3</sup> or classified by the investigator as neutropenic at baseline) with microbiologically confirmed invasive candidiasis was assessed in an analysis of pooled data from 5 prospective studies (1 comparative versus caspofungin and 4 open-label, non-comparative). Patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy</p><p>&nbsp;</p><p>was permitted after at least 5 to 10 days of treatment with anidulafungin. A total of 46 patients were included in the analysis. The majority of patients had candidaemia only (84.8%; 39/46). The most common&nbsp;&nbsp; pathogens&nbsp;&nbsp; isolated&nbsp;&nbsp; at&nbsp;&nbsp; baseline&nbsp;&nbsp; were <em>C.&nbsp;&nbsp; tropicalis </em>(34.8%;&nbsp;&nbsp; 16/46), <em>C. krusei </em>(19.6%; 9/46), <em>C.&nbsp;&nbsp; parapsilosis </em>(17.4%;&nbsp;&nbsp; 8/46), <em>C.&nbsp;&nbsp; albicans </em>(15.2%;&nbsp;&nbsp; 7/46), and <em>C. glabrata </em>(15.2%; 7/46). The successful global response rate at End of Intravenous Treatment (primary endpoint) was 26/46 (56.5%) and End of All Treatment was 24/46 (52.2%). All-cause mortality up to the end of the study (6 Week Follow-up Visit) was 21/46 (45.7%).</p><p>The efficacy of anidulafungin in adult neutropenic patients (defined as absolute neutrophil count</p><p>&le;500 cells/mm<sup>3</sup> at baseline) with invasive candidiasis was assessed in a prospective, double-blind, randomized, controlled trial. Eligible patients received either anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) or caspofungin (70 mg intravenous loading dose followed by 50 mg intravenous daily) (2:1 randomization). Patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 10 days of study treatment. A total of 14 neutropenic patients with microbiologically confirmed invasive candidiasis (MITT population) were enrolled in the study (11 anidulafungin; 3 caspofungin). The majority of patients had candidaemia only. The most common pathogens isolated at baseline were <em>C. tropicalis </em>(4 anidulafungin, 0 caspofungin), <em>C. parapsilosi</em>s (2 anidulafungin,&nbsp;&nbsp; 1 caspofungin), <em>C.&nbsp;&nbsp; krusei </em>(2&nbsp;&nbsp; anidulafungin,&nbsp;&nbsp; 1&nbsp;&nbsp; caspofungin), and <em>C. ciferrii </em>(2 anidulafungin, 0 caspofungin). The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 8/11 (72.7%) for anidulafungin and 3/3 (100.0%) for caspofungin (difference -27.3, 95% CI -80.9, 40.3); the successful global response rate at the End of All Treatment was 8/11 (72.7%) for anidulafungin and 3/3 (100.0%) for caspofungin (difference -27.3, 95% CI -80.9, 40.3). All-cause mortality up to the 6 Week Follow-Up visit for anidulafungin (MITT population) was 4/11 (36.4%) and 2/3 (66.7%) for caspofungin.</p><p>Patients with microbiologically confirmed invasive candidiasis (MITT population) and neutropenia were identified in an analysis of pooled data from 4 similarly designed prospective, open-label, non-comparative studies. The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) was assessed in 35 adult neutropenic patients defined as absolute neutrophil count &le; 500 cells/mm<sup>3</sup> or WBC &le; 500 cells/mm<sup>3</sup> in 22 patients or classified by the investigator as neutropenic at baseline in 13 patients. All patients were treated for at least 14 days. In clinically stable patients, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. The majority of patients had candidaemia only (85.7%). The most common&nbsp;&nbsp; pathogens&nbsp;&nbsp; isolated&nbsp;&nbsp; at&nbsp;&nbsp; baseline&nbsp;&nbsp; were <em>C.&nbsp;&nbsp; tropicalis </em>(12&nbsp;&nbsp; patients),</p><p><em>C. albicans </em>(7 patients), <em>C. glabrata </em>(7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients), <em>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; krusei </em>(7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients), and <em>C. parapsilosis </em>(6 patients). The successful global response rate at the End of Intravenous Treatment (primary endpoint) was 18/35 (51.4%) and 16/35 (45.7%) at the End of All Treatment. All-cause mortality by Day 28 was 10/35 (28.6%). The successful global response rate at End of Intravenous Treatment and End of All Treatment were both 7/13 (53.8%) in the 13 patients with neutropenia assessed by investigators at baseline.</p><p>&nbsp;</p><p>Additional Data in Patients with Deep Tissue Infections</p><p>The efficacy of anidulafungin (200 mg intravenous loading dose followed by 100 mg intravenous daily) in adult patients with microbiologically confirmed deep tissue candidiasis was assessed in an analysis of pooled data from 5 prospective studies (1 comparative and 4 open-label). Patients were treated for at least 14 days. In the 4 open-label studies, a switch to oral azole therapy was permitted after at least 5 to 10 days of treatment with anidulafungin. A total of 129 patients were included in the analysis. Twenty-one (16.3%) had concomitant candidaemia. The mean APACHE II score was</p><p>14.9 (range, 2 &ndash; 44). The most common sites of infection included the peritoneal cavity (54.3%; 70 of 129), hepatobiliary tract (7.0%; 9 of 129), pleural cavity (5.4%; 7 of 129) and kidney (3.1%; 4 of 129). The most common pathogens isolated from a deep tissue site at baseline were <em>C. albicans </em>(64.3%; 83 of 129), <em>C. glabrata </em>(31.0%; 40 of 129), <em>C. tropicalis </em>(11.6%; 15 of 129), and <em>C. krusei </em>(5.4%; 7 of 129). The successful global response rate at the end of intravenous treatment (primary endpoint) and end of all treatment and all-cause mortality up to the 6 week follow-up visit is shown in Table 5.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 5. Rate of Successful Global Response<sup>a</sup> and All-Cause Mortality in Patients with Deep Tissue Candidiasis &ndash; Pooled Analysis</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>MITT Population n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Global Response of Success at EOIVT<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Overall</p></td><td style="vertical-align:top"><p>102/129 (79.1)</p></td></tr><tr><td style="vertical-align:top"><p>Peritoneal cavity</p></td><td style="vertical-align:top"><p>51/70 (72.9)</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary tract</p></td><td style="vertical-align:top"><p>7/9 (77.8)</p></td></tr><tr><td style="vertical-align:top"><p>Pleural cavity</p></td><td style="vertical-align:top"><p>6/7 (85.7)</p></td></tr><tr><td style="vertical-align:top"><p>Kidney</p></td><td style="vertical-align:top"><p>3/4 (75.0)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 5. Rate of Successful Global Response<sup>a</sup> and All-Cause Mortality in Patients with Deep Tissue Candidiasis &ndash; Pooled Analysis</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>MITT Population n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Global Response of Success at EOIVT<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Global Response of Success at EOT<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>94/129 (72.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>All-Cause Mortality</strong></p></td><td style="vertical-align:top"><p>40/129 (31.0)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup> successful global response was defined as both clinical and microbiologic success</p><p><sup>b</sup> EOIVT, End of Intravenous Treatment; EOT, End of All Treatment</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>A prospective, open-label, non-comparative, multi-national study assessed the safety and efficacy of anidulafungin in 68 paediatric patients aged 1 month to &lt; 18 years with invasive candidiasis including candidaemia (ICC). Patients were stratified by age (1 month to &lt; 2 years, 2 to &lt; 5 years, and 5 to &lt; 18 years) and received once daily intravenous anidulafungin (3.0 mg/kg loading dose on Day 1, and 1.5 mg/kg daily maintenance dose thereafter) for up to 35 days followed by an optional switch to oral fluconazole (6-12 mg/kg/day, maximum 800 mg/day). Patients were followed at 2 and 6 weeks after EOT.</p><p>Among&nbsp; 68&nbsp; patients&nbsp; who&nbsp; received&nbsp; anidulafungin,&nbsp; 64&nbsp; had&nbsp; microbiologically confirmed <em>Candida </em>infection and were evaluated for efficacy in the modified intent-to-treat (MITT) population. Overall, 61 patients (92.2%) had <em>Candida </em>isolated from blood only. The most commonly isolated pathogens were <em>Candida albicans </em>(25 [39.1%] patients), followed by <em>Candida parapsilosis </em>(17 [26.6%] patients), and <em>Candida tropicalis </em>(9 [14.1%] patients). A successful global response was defined as having both a clinical response of success (cure or improvement) and a microbiological response of success (eradication or presumed eradication). The overall rates of successful global response in the MITT population are presented in Table 6.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 6. Summary of Successful Global Response by Age Group, MITT Population</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Successful Global Response, n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Timepoint</strong></p></td><td style="vertical-align:top"><p><strong>Global Response</strong></p></td><td style="vertical-align:top"><p><strong>1 month to &lt; 2 years (N=16)</strong></p><p><strong>n (n/N, %)</strong></p></td><td style="vertical-align:top"><p><strong>2 to &lt; 5 years (N=18)</strong></p><p><strong>n (n/N, %)</strong></p></td><td style="vertical-align:top"><p><strong>5 to &lt; 18 years (N=30)</strong></p><p><strong>n (n/N, %)</strong></p></td><td style="vertical-align:top"><p><strong>Overall (N=64)</strong></p><p><strong>n (n/N, %)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>EOIVT</strong></p></td><td style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>14 (77.8)</p></td><td style="vertical-align:top"><p>20 (66.7)</p></td><td style="vertical-align:top"><p>45 (70.3)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(52.4, 93.6)</p></td><td style="vertical-align:top"><p>(47.2, 82.7)</p></td><td style="vertical-align:top"><p>(57.6, 81.1)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>EOT</strong></p></td><td style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>14 (77.8)</p></td><td style="vertical-align:top"><p>21 (70.0)</p></td><td style="vertical-align:top"><p>46 (71.9)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(52.4, 93.6)</p></td><td style="vertical-align:top"><p>(50.6, 85.3)</p></td><td style="vertical-align:top"><p>(59.2, 82.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>2-week FU</strong></p></td><td style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>13 (72.2)</p></td><td style="vertical-align:top"><p>22 (73.3)</p></td><td style="vertical-align:top"><p>46 (71.9)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(46.5, 90.3)</p></td><td style="vertical-align:top"><p>(54.1, 87.7)</p></td><td style="vertical-align:top"><p>(59.2, 82.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>6-week FU</strong></p></td><td style="vertical-align:top"><p>Success</p></td><td style="vertical-align:top"><p>11 (68.8)</p></td><td style="vertical-align:top"><p>12 (66.7)</p></td><td style="vertical-align:top"><p>20 (66.7)</p></td><td style="vertical-align:top"><p>43 (67.2)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI</p></td><td style="vertical-align:top"><p>(41.3, 89.0)</p></td><td style="vertical-align:top"><p>(41.0, 86.7)</p></td><td style="vertical-align:top"><p>(47.2, 82.7)</p></td><td style="vertical-align:top"><p>(54.3, 78.4)</p></td></tr></tbody></table><p>95% CI = exact 95% confidence interval for binomial proportions using Clopper-Pearson method; EOIVT = End of Intravenous Treatment; EOT = End of All Treatment; FU = follow-up; MITT = modified intent-to-treat; N = number of subjects in the population; n = number of subjects with responses.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetic characteristics</u></p><p>The pharmacokinetics of anidulafungin have been characterised in healthy subjects, special populations and patients. A low intersubject variability in systemic exposure (coefficient of variation ~25%) was observed. The steady state was achieved on the first day after a loading dose (twice the daily maintenance dose).</p><p><u>Distribution</u></p><p>The pharmacokinetics of anidulafungin are characterised by a rapid distribution half-life (0.5-1 hour) and a volume of distribution, 30-50 l, which is similar to total body fluid volume. Anidulafungin is extensively bound (&gt;99%) to human plasma proteins. No specific tissue distribution studies of anidulafungin have been done in humans. Therefore, no information is available about the penetration of anidulafungin into the cerebrospinal fluid (CSF) and/or across the blood-brain barrier.</p><p><u>Biotransformation</u></p><p>Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes. It is unlikely that anidulafungin will have clinically relevant effects on the metabolism of drugs metabolised by cytochrome P450 isoenzymes.</p><p>&nbsp;</p><p>Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. The <em>in vitro </em>degradation half-life of anidulafungin under physiologic conditions is approximately 24 hours. <em>In vivo</em>, the ring-opened product is subsequently converted to peptidic degradants and eliminated mainly through biliary excretion.</p><p><u>Elimination</u></p><p>The clearance of anidulafungin is about 1 l/h. Anidulafungin has a predominant elimination half-life of approximately 24 hours that characterizes the majority of the plasma concentration-time profile, and a terminal half-life of 40-50 hours that characterises the terminal elimination phase of the profile.</p><p>In a single-dose clinical study, radiolabeled (<sup>14</sup>C) anidulafungin (~88 mg) was administered to healthy subjects. Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug. Less than 1% of the administered radioactive dose was excreted in the urine, indicating negligible renal clearance. Anidulafungin concentrations fell below the lower limits of quantitation 6 days post-dose. Negligible amounts of drug-derived radioactivity were recovered in blood, urine, and faeces 8 weeks post-dose.</p><p><u>Linearity</u></p><p>Anidulafungin displays linear pharmacokinetics across a wide range of once daily doses (15-130 mg).</p><p><u>Special populations</u></p><p><em>Patients with fungal infections</em></p><p>The pharmacokinetics of anidulafungin in patients with fungal infections are similar to those observed in healthy subjects based on population pharmacokinetic analyses. With the 200/100 mg daily dose regimen at an infusion rate of 1.1 mg/min, the steady state C<sub>max</sub> and trough concentrations (C<sub>min</sub>) could reach approximately 7 and 3 mg/L, respectively, with an average steady state AUC of approximately 110 mg&bull;h/L.</p><p><em>Weight</em></p><p>Although weight was identified as a source of variability in clearance in the population pharmacokinetic analysis, weight has little clinical relevance on the pharmacokinetics of anidulafungin.</p><p><em>Gender</em></p><p>Plasma concentrations of anidulafungin in healthy men and women were similar. In multiple-dose patient studies, drug clearance was slightly faster (approximately 22%) in men.</p><p><em>Elderly</em></p><p>The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients &ge; 65, median CL = 1.07 l/h) and the non-elderly group (patients &lt; 65, median CL = 1.22 l/h), however the range of clearance was similar.</p><p><em>Ethnicity</em></p><p>Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.</p><p><em>HIV positivity</em></p><p>Dosage adjustments are not required based on HIV positivity, irrespective of concomitant anti-retroviral therapy.</p><p><em>Hepatic insufficiency</em></p><p>Anidulafungin is not hepatically metabolised. Anidulafungin pharmacokinetics were examined in subjects with Child-Pugh class A, B or C hepatic insufficiency. Anidulafungin concentrations were not increased in subjects with any degree of hepatic insufficiency. Although a slight decrease in AUC was observed in patients with Child-Pugh C hepatic insufficiency, the decrease was within the range of population estimates noted for healthy subjects.</p><p><em>Renal insufficiency</em></p><p>Anidulafungin has negligible renal clearance (&lt;1%). In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function. Anidulafungin is not dialysable and may be administered without regard to the timing of hemodialysis.</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of anidulafungin after at least 5 daily doses were investigated in 24 immunocompromised paediatric (2 to 11 years old) and adolescent (12 to 17 years old) patients with neutropenia. Steady state was achieved on the first day after a loading dose (twice the maintenance dose), and steady state C<sub>max</sub> and AUC<sub>ss</sub> increase in a dose-proportional manner. Systemic exposure following daily maintenance dose of 0.75 and 1.5 mg/kg/day in this population were comparable to those observed in adults following 50 and 100 mg/day, respectively. Both regimens were well-tolerated by these patients.</p><p>&nbsp;</p><p>The pharmacokinetics of anidulafungin was investigated in 66 paediatric patients (1 month to</p><p>&lt;18 years) with ICC in a prospective, open-label, non-comparative paediatric study following administration of 3.0 mg/kg loading dose and 1.5 mg/kg/day maintenance dose (see section 5.1). Based on population pharmacokinetic analysis of combined data from adult and paediatric patients with ICC, the mean exposure parameters (AUC<sub>0-24,ss</sub> and C<sub>min,ss</sub>) at steady state in the overall paediatric patients across age groups (1 month to &lt; 2 years, 2 to &lt; 5 years, and 5 to &lt; 18 years) were comparable to those in adults receiving 200 mg loading dose and 100 mg/day maintenance dose. Body weight adjusted CL (L/h/kg) and volume of distribution at steady state (L/kg) were similar across the age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 3-month studies, evidence of liver toxicity, including elevated enzymes and morphologic alterations, was observed in both rats and monkeys at doses 4- to 6-fold higher than the anticipated clinical therapeutic exposure. <em>In vitro </em>and <em>in vivo </em>genotoxicity studies with anidulafungin provided no evidence of genotoxic potential. Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of anidulafungin.</p><p>Administration of anidulafungin to rats did not indicate any effects on reproduction, including male and female fertility.</p><p>Anidulafungin crossed the placental barrier in rats and was detected in foetal plasma.</p><p>Embryo-foetal development studies were conducted with doses between 0.2- and 2-fold (rats) and between 1- and 4-fold (rabbits) the proposed therapeutic maintenance dose of 100 mg/day. Anidulafungin did not produce any drug-related developmental toxicity in rats at the highest dose tested. Developmental effects observed in rabbits (slightly reduced foetal weights) occurred only at the highest dose tested, a dose that also produced maternal toxicity.</p><p>The concentration of anidulafungin in the brain was low (brain to plasma ratio of approximately 0.2) in uninfected adult and neonatal rats after a single dose. However, brain concentrations increased in uninfected neonatal rats after five daily doses (brain to plasma ratio of approximately 0.7). In multiple dose studies in rabbits with disseminated candidiasis and in mice with central nervous system (CNS) candida infection, anidulafungin has been shown to reduce fungal burden in the brain.</p><p>Results of pharmacokinetic-pharmacodynamic studies in rabbit models of disseminated candidiasis and hematogenous <em>Candida </em>meningoencephalitis indicated that higher doses of anidulafungin were needed to optimally treat infections of CNS tissues relative to non-CNS tissues (see section 4.4).</p><p>Rats were dosed with anidulafungin at three dose levels and anaesthetised within one hour using a combination of ketamine and xylazine. Rats in the high dose group experienced infusion-related reactions that were exacerbated by anaesthesia. Some rats in the mid dose group experienced similar reactions but only after administration of anaesthesia. There were no adverse reactions in the low-dose animals in the presence or absence of anaesthesia, and no infusion-related reactions in the mid-dose group in the absence of anaesthesia.</p><p>Studies conducted in juvenile rats did not indicate a greater susceptibility to anidulafungin hepatotoxicity compared to adult animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tartaric acid Sucrose Polysorbate 80 Sodium hydroxide Hydrochloric acid</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products or electrolytes except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
Reconstituted solution:
Chemical and physical in-use stability of the reconstituted solution has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, following good aseptic practices, the reconstituted solution can be utilized for up to 24 hours when stored at 25°C.
 
Infusion solution:
Do not freeze.
Chemical and physical in-use stability of the infusion solution has been demonstrated for 48 hours at 25°C.
From a microbiological point of view, following good aseptic practices, the infusion solution can be utilized for up to 48 hours from preparation when stored at 25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2<sup>o</sup>C &ndash; 8<sup>o</sup>C).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anidulafungin TBM is packaged in type I colourless glass vials, closed with type I butyl rubber stopper and aluminium metallic caps with polypropylene disk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no special requirements for disposal.</p><p>Anidulafungin TBM must be reconstituted with water for injections and subsequently diluted with ONLY sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose for infusion. The compatibility of reconstituted Anidulafungin TBM with intravenous substances, additives, or medicines other than 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion has not been established. The infusion solution must not be frozen.</p><p><u>Reconstitution</u></p><p>Aseptically reconstitute each vial with 30 mL water for injections to provide a concentration of</p><p>3.33 mg/mL. The reconstitution time can be up to 5 mins. After subsequent dilution, the solution is to be discarded if particulate matter or discoloration is identified.</p><p><u>Dilution and infusion</u></p><p>Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. If particulate matter or discolouration is identified, discard the solution.</p><p><u>Adult Patients</u></p><p>Aseptically transfer the contents of the reconstituted vial(s) into an intravenous bag (or bottle) containing either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion to obtain the appropriate Anidulafungin TBM concentration. The table below provides the dilution to a concentration of 0.77 mg/mL for the final infusion solution and infusion instructions for each dose.</p><p><u>Dilution requirements for Anidulafungin TBM administration</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials of powder</strong></p></td><td style="vertical-align:top"><p><strong>Total reconstituted volume</strong></p></td><td style="vertical-align:top"><p><strong>Infusion volume<sup>A</sup></strong></p></td><td style="vertical-align:top"><p><strong>Total infusion volume<sup>B</sup></strong></p></td><td style="vertical-align:top"><p><strong>Rate of infusion</strong></p></td><td style="vertical-align:top"><p><strong>Minimum duration of infusion</strong></p></td></tr><tr><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>30 mL</p></td><td style="vertical-align:top"><p>100 mL</p></td><td style="vertical-align:top"><p>130 mL</p></td><td style="vertical-align:top"><p>1.4 mL/min or 84 mL/ hour</p></td><td style="vertical-align:top"><p>90 min</p></td></tr><tr><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>60 mL</p></td><td style="vertical-align:top"><p>200 mL</p></td><td style="vertical-align:top"><p>260 mL</p></td><td style="vertical-align:top"><p>1.4 mL/min or 84 mL/ hour</p></td><td style="vertical-align:top"><p>180 min</p></td></tr></tbody></table><p><sup>A</sup> Either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion.</p><p><sup>B</sup> Infusion solution concentration is 0.77 mg/mL.</p><p>The rate of infusion should not exceed 1.1 mg/min (equivalent to 1.4 mL/min or 84 mL/hour when reconstituted and diluted per instructions) (see sections 4.2, 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Paediatric Patients</u></p><p>For paediatric patients aged 1 month to &lt;18 years, the volume of infusion solution required to deliver the dose will vary depending on the weight of the patient. The reconstituted solution must be further diluted to a concentration of 0.77 mg/mL for the final infusion solution. A programmable syringe or infusion pump is recommended. <strong>The rate of infusion should not exceed 1.1 mg/minute (equivalent to 1.4 mL/minute or 84 mL/hour when reconstituted and diluted per instructions) </strong>(see sections 4.2 and 4.4).</p><p>1.&nbsp;&nbsp; Calculate patient dose and reconstitute vial(s) required according to reconstitution instructions to provide a concentration of 3.33 mg/mL (see sections 2 and 4.2).</p><p>2.&nbsp;&nbsp; Calculate the volume (mL) of reconstituted anidulafungin required:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Volume of anidulafungin (mL)</u> = Dose of anidulafungin (mg) &divide; 3.33 mg/mL</p><p>&nbsp;</p><p>3.&nbsp;&nbsp; Calculate the total volume of dosing solution (mL) required to provide a final concentration of</p><p>0.77 mg/mL:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Total volume of dosing solution (mL)</u> = Dose of anidulafungin (mg) &divide; 0.77 mg/mL</p><p>4.&nbsp;&nbsp; Calculate the volume of diluent [5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline)] required to prepare the dosing solution:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Volume of diluent (mL)</u> = Total volume of dosing solution (mL) &ndash; Volume of anidulafungin (mL)</p><p>5.&nbsp;&nbsp; Aseptically transfer the required volumes (mL) of anidulafungin and 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline) into an infusion syringe or IV infusion bag needed for administration.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company, Tadawi Biomedical- KSA Riyadh, Sudair Industrial Area, Zone A, Road 11, Factory 107, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>